Explore All Access
Check if your research matches the topics covered in Leukemia and Lymphoma?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Leukemia and Lymphoma : Impact Factor & More
eISSN: 1029-2403pISSN: 1042-8194
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Leukemia and Lymphoma Key Metrics
CiteScore 
4.2
Impact Factor
< 5
SNIP
0.79
Time to Publish
4
Mo
Time to Publish
% of papers by time taken from submission to publication
0 to 3 months27%
4 to 6 months52%
7 to 9 months17%
Above 9 months4%
Did you find this useful?
Leukemia and Lymphoma Journal Specifications
Indexed in the following public directories
Scopus 
SJR
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1989 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Leukemia and Lymphoma ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Leukemia and Lymphoma
MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
- 22 Oct 2024
- Leukemia & lymphoma
Blinatumomab use in patients with CD19 positive B-ALL and hepatic dysfunction.
- 22 Oct 2024
- Leukemia & lymphoma
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis.
- 21 Oct 2024
- Leukemia & lymphoma
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?
- 20 Oct 2024
- Leukemia & lymphoma
Daratumumab-induced rhabdomyolysis in multiple myeloma: a rare case report
- 17 Oct 2024
- Leukemia & Lymphoma
Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia
- 17 Oct 2024
- Leukemia & Lymphoma
MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
- 22 Oct 2024
- Leukemia & lymphoma
Blinatumomab use in patients with CD19 positive B-ALL and hepatic dysfunction.
- 22 Oct 2024
- Leukemia & lymphoma
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis.
- 21 Oct 2024
- Leukemia & lymphoma
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?
- 20 Oct 2024
- Leukemia & lymphoma
Daratumumab-induced rhabdomyolysis in multiple myeloma: a rare case report
- 17 Oct 2024
- Leukemia & Lymphoma
Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia
- 17 Oct 2024
- Leukemia & Lymphoma
FAQs on Leukemia and Lymphoma
How long has Leukemia and Lymphoma been actively publishing? 
Leukemia and Lymphoma has been in operation since 1989 till date.
What is the publishing frequency of Leukemia and Lymphoma?
Leukemia and Lymphoma published with a Monthly frequency.
How many articles did Leukemia and Lymphoma publish last year?
In 2023, Leukemia and Lymphoma publsihed 286 articles.
What is the eISSN & pISSN for Leukemia and Lymphoma?
For Leukemia and Lymphoma, eISSN is 1029-2403 and pISSN is 1042-8194.
What is Citescore for Leukemia and Lymphoma?
Citescore for Leukemia and Lymphoma is 4.2.
What is SNIP score for Leukemia and Lymphoma?
SNIP score for Leukemia and Lymphoma is 0.79.
Who is the publisher of Leukemia and Lymphoma?
TAYLOR & FRANCIS LTD is the publisher of Leukemia and Lymphoma.
